Welcome to our dedicated page for Lifemd news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
News for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) is closely tied to developments at LifeMD, Inc., the issuer of this preferred security. LifeMD regularly publishes updates about its virtual primary care and pharmacy operations, financing activities, and corporate governance, all of which can be relevant to investors following LFMDP.
Company announcements describe LifeMD as a provider of virtual primary care services and pharmacy solutions, with telemedicine, laboratory access, and pharmacy services supporting treatment across more than 200 conditions. News items highlight growth in telehealth revenue, expansion into areas such as weight management, women’s health, mental and behavioral health, and cardiometabolic care initiatives, and the evolution of its virtual care platform.
Investors tracking LFMDP can expect news related to LifeMD’s clinical programs, including collaborations with pharmaceutical manufacturers. Recent releases discuss expanded collaboration with Novo Nordisk, access to Wegovy and Ozempic within LifeMD’s weight management program, and the addition of the Wegovy pill to its virtual obesity care offering. Other updates cover developments in women’s health programs, including the appointment of clinical advisors, and the scaling of men’s health and RexMD-branded services.
Corporate and financial news is also significant for LFMDP followers. LifeMD has issued press releases on quarterly financial results, changes in independent registered public accounting firms, the divestiture of its majority interest in WorkSimpli Software LLC to focus on virtual care and pharmacy, and the establishment of a revolving credit facility. The company has additionally announced quarterly cash dividends on the 8.875% Series A Cumulative Perpetual Preferred Stock.
By reviewing the LFMDP news feed, readers can monitor how LifeMD’s virtual care strategy, partnerships, financial decisions, and governance updates may influence the context in which this preferred stock operates. Regular news provides a consolidated view of operational milestones and capital structure developments that matter to preferred and common equity holders alike.
LifeMD (NASDAQ: LFMD) reported strong Q3 2024 results with total revenues increasing 38% year-over-year to $53.4 million, driven by 65% growth in telehealth revenue. The company achieved a record gross margin of 90.6% and Adjusted EBITDA of $3.7 million. Telehealth subscribers grew 30% to 269,000, while telehealth adjusted EBITDA reached $2.5 million. The company maintained strong cash position of $37.6 million and generated $6.2 million in operating cash flow. For Q4 2024, LifeMD expects revenues between $57-58 million and adjusted EBITDA of $6.5-7.0 million.
LifeMD (NASDAQ: LFMD) has launched its state-of-the-art affiliated pharmacy in Lancaster, PA, completing its end-to-end telehealth platform. The 22,500-square-foot facility can process up to 5,000 daily prescriptions and is expected to be licensed across all 50 states, DC, and Puerto Rico by year-end. This integration is projected to generate $5 million in annualized expense savings. The pharmacy enhances LifeMD's vertically integrated platform, which includes proprietary virtual-care technology, a 50-state medical group, and a U.S.-based patient care center. The facility will enable personalized care packages and bundled shipments combining prescriptions and wellness products.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has scheduled its third quarter 2024 financial results announcement for November 7, 2024, after U.S. market close. The company will host a conference call at 4:30 p.m. Eastern time, accessible via toll-free (800-717-1738) and international (646-307-1865) dial-in numbers, with conference ID 73461.
LifeMD, Inc. (Nasdaq: LFMD), a leading virtual primary care services provider, has announced a quarterly cash dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend, authorized by the company's Board of Directors, amounts to $0.5546875 per share. Shareholders of record as of the close of business on October 4, 2024, will receive the dividend payment on October 15, 2024. This announcement demonstrates LifeMD's commitment to providing returns to its preferred stockholders.
LifeMD (Nasdaq: LFMD) has announced major enhancements to its weight management program, expanding patient access to branded GLP-1 therapies and introducing new treatment options. The company has implemented a real-time electronic benefit verification program and partnered with an AI-powered platform to optimize prior authorization submissions. These improvements are estimated to increase LifeMD's addressable weight loss market by 15%.
Key advancements include:
- Integration of at-home, self-collection laboratory testing services
- Launch of a personalized therapy alternative to GLP-1 medications
- Improved pharmacy benefits infrastructure
Over the past 30 days, 38% of patients providing insurance information received affordable coverage for branded GLP-1 medication, with expectations to exceed 50% soon.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced its participation in three major investor conferences in September 2024. The company's management will attend:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11) in New York, featuring a corporate presentation on Sept. 9 at 12:00 p.m. ET.
2. TD Cowen 9th Annual FutureHealth Conference (Sept. 10) in New York, participating in a panel discussion at 2:20 p.m. ET.
3. Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19) in New York, with a fireside chat on Sept. 18 at 8:35 a.m. ET.
At these events, LifeMD's management will engage in one-on-one meetings with investors, showcasing the company's progress and future prospects in the virtual healthcare sector.
LifeMD (LFMD) reported strong Q2 2024 results, with revenue increasing 41% year-over-year to $50.7 million. Telehealth revenue grew 67%, and the segment achieved profitability one quarter ahead of guidance with adjusted EBITDA of $820,000. Key highlights include:
- Telehealth active subscribers increased 32% to 254,000
- Weight management subscribers exceeded 60,000
- Gross margin expanded to 90%
- Adjusted EBITDA increased 44% to $2.5 million
- Cash position of $35.7 million as of June 30, 2024
The company raised its 2024 telehealth revenue guidance to $150 million and introduced telehealth adjusted EBITDA guidance of $3-4 million. However, due to WorkSimpli's underperformance, consolidated adjusted EBITDA guidance was revised to $13-15 million.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced it will release its Q2 2024 financial results on August 7, 2024, after U.S. financial markets close. The company will host a conference call at 4:30 p.m. Eastern time on the same day to discuss the results. Investors can access the call via toll-free (1-800-245-3047) or international (1-203-518-9765) dial-in numbers, using the conference ID: LIFEMD. A live and archived webcast of the call will also be available.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced its participation in two major investor conferences in August 2024. The company will attend the KeyBanc Capital Markets Technology Leadership Forum from August 4-6 in Vail, Colorado, where management will engage in a fireside chat on August 5th and conduct one-on-one investor meetings.
Additionally, LifeMD will be present at the Canaccord Genuity 44th Annual Growth Conference from August 13-15 at the InterContinental Boston hotel. During this event, the management team will deliver a corporate overview on August 14th and hold individual meetings with investors. These conferences provide LifeMD with valuable opportunities to showcase its business model and growth strategies to potential investors and industry analysts.
LifeMD (NASDAQ: LFMD/LFMDP) has announced a quarterly cash dividend for its 8.875% Series A Cumulative Perpetual Preferred Stock. The dividend amounts to $0.5546875 per share and will be paid on July 15, 2024, to shareholders of record as of July 5, 2024. This marks a continued commitment to providing returns to shareholders.
FAQ
What is the current stock price of Lifemd (LFMDP)?
